Identifier |
20230315_nanos_neuroimmunology1_02 |
Title |
MS Treatment/Immune System Targets |
Creator |
Robert K. Shin |
Affiliation |
MedStar Georgetown University Hospital; Washington, DC |
Subject |
Demyelination; Multiple Sclerosis; Disease-Modifying Therapy; Relapsing; Progressive |
Description |
Beta interferons and glatiramer acetate were the first MS disease modifying therapies, FDA-approved in the 1990s. They are only moderately effective compared to more modern MS treatment options, but they are felt to be generally safe and well-tolerated. Injection-related side effects are common. |
Date |
2023-03 |
Language |
eng |
Format |
application/pdf |
Type |
Text |
Source |
2023 North American Neuro-Ophthalmology Society Annual Meeting |
Relation is Part of |
NANOS Annual Meeting 2023: Neuroimmunology |
Collection |
Neuro-ophthalmology Virtual Education Library: NOVEL http://NOVEL.utah.edu |
Publisher |
Spencer S. Eccles Health Sciences Library, University of Utah |
Holding Institution |
North American Neuro-Ophthalmology Association. NANOS Executive Office 5841 Cedar Lake Road, Suite 204, Minneapolis, MN 55416 |
Rights Management |
Copyright 2023. For further information regarding the rights to this collection, please visit: https://NOVEL.utah.edu/about/copyright |
ARK |
ark:/87278/s6m9vs33 |
Context URL |
The NANOS Annual Meeting Neuro-Ophthalmology Collection: https://novel.utah.edu/collection/NAM/toc/ |
Setname |
ehsl_novel_nam |
ID |
2309966 |
Reference URL |
https://collections.lib.utah.edu/ark:/87278/s6m9vs33 |